Novo Nordisk has agreed to buy Akero Therapeutics and its drug candidate for metabolic dysfunction-associated steatohepatitis (MASH) for $4.7 billion upfront, shortly after claiming FDA approval to ...
Boehringer Ingelheim’s weight-loss drug candidate survodutide could also be effective for liver disease metabolic dysfunction-associated steatohepatitis (MASH), if the results of a mid-stage trial are ...
Over the last 20 years Monster Hunter has delivered some of the most memorable, over-the-top monster designs that have scared, delighted, and stunned fans in equal measure. Whether your first hunt ...
Sea monsters have a prominent role in the myths and legends of most seafaring cultures on Earth. With such inspiring ocean biodiversity, it’s not difficult to see why. Join Oliver Crimmen, our ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results